Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Retinitis Pigmentosa Clinical Trials

57 recruiting trials for Retinitis Pigmentosa. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
57
Total Trials
57
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT02435940

Inherited Retinal Degenerative Disease Registry

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by...

Sponsor: Foundation Fighting BlindnessEnrolling: 200001 location
RECRUITINGNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international...

Sponsor: Sanford HealthEnrolling: 200002 locations
RECRUITINGNCT04129021

High Resolution, High-speed Multimodal Ophthalmic Imaging

Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical...

Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsEnrolling: 12001 location
RECRUITINGNCT02617966

Rod and Cone Mediated Function in Retinal Disease

Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone...

Sponsor: National Eye Institute (NEI)Enrolling: 5001 location
RECRUITINGNCT01432847

Cell Collection to Study Eye Diseases

Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light...

Sponsor: National Eye Institute (NEI)Enrolling: 9301 location
RECRUITINGNCT05355415

Adaptive Optics Imaging of Outer Retinal Diseases

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor,...

Sponsor: Food and Drug Administration (FDA)Enrolling: 1002 locations
RECRUITINGNCT03011541

Stem Cell Ophthalmology Treatment Study II

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Sponsor: MD Stem CellsEnrolling: 5004 locations
RECRUITINGNCT02014389

Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer

Objective perimetry can better monitor visual field defects in retinal dystrophy and Glaucoma patients than conventional subjective perimetry. The PLR ( Pupil Light Reflex to...

Sponsor: Sheba Medical CenterEnrolling: 2001 location
RECRUITINGPhase 1NCT05147701

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of...

Sponsor: The Foundation for Orthopaedics and Regenerative MedicineEnrolling: 202 locations
RECRUITINGNCT04461444

COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study

ALMS and BBS syndromes are rare diseases with overlapping features of multiple sensory and metabolic impairments, including diabetes mellitus. There are to date no specific...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 3501 location
RECRUITINGPhase 1 / Phase 2NCT06242379

Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa

The aim of this clinical trials is to evaluate the safety and efficacy of intravitreal injection of GMP-compliant BM-MSC-derived sEVs in patients with retinitis pigmentosa.

Sponsor: Mahidol UniversityEnrolling: 151 location
RECRUITINGNCT05554835

Global Registry and Natural History Study for Mitochondrial Disorders

The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and...

Sponsor: LMU KlinikumEnrolling: 600018 locations
RECRUITINGNCT03635645

Experimental and Clinical Studies of Retinal Stimulation

The study will evaluate new methods of retinal stimulation and training with the goal of improving the visual ability of retinal prosthesis participants.

Sponsor: University of MichiganEnrolling: 201 location
RECRUITINGNCT00874783

Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases

Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5). The...

Sponsor: Hadassah Medical OrganizationEnrolling: 1201 location
RECRUITINGNCT07126470

Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients

This is a self-controlled randomized clinical trial to investigate the effect of capsular tension ring (CTR) implantation on intraocular lens (IOL) position in cataract patients...

Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen UniversityEnrolling: 881 location
RECRUITINGPhase 1 / Phase 2NCT07408232

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and...

Sponsor: Octant, Inc.Enrolling: 501 location
RECRUITINGNCT01401998

ARPKD Database Study

Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and other diseases with...

Sponsor: Children's Hospital of PhiladelphiaEnrolling: 2006 locations
RECRUITINGNCT07292987

Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

This study explores whether adding early nurse-led and psychological support after the diagnosis of retinitis pigmentosa (RP) can improve patient experience and emotional...

Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsEnrolling: 801 location
RECRUITINGNCT07278843

Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests...

Inherited retinal diseases (IRDs) are a group of degenerative disorders that cause progressive vision loss. Retinitis pigmentosa (RP) is the most common form, with a global...

Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsEnrolling: 601 location
RECRUITINGPhase 3NCT05926583

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase...

Sponsor: Janssen Pharmaceutical K.K.Enrolling: 41 location
RECRUITINGEarly Phase 1NCT06292650

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in...

Sponsor: Zhongmou TherapeuticsEnrolling: 121 location
RECRUITINGNCT01694940

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.

Sponsor: Columbia UniversityEnrolling: 100017 locations
RECRUITINGNCT07228793

Natural History Study of Patients With EYS-Associated RP

This natural history study of patients with EYS mutations from Russia and former CIS (Commonwealth of Independent States) territories will accelerate the development of outcome...

Sponsor: Sensor Technology for DeafblindEnrolling: 451 location
RECRUITINGNCT04463316

GROWing Up With Rare GENEtic Syndromes

Introduction Rare complex syndromes Patients with complex genetic syndromes, by definition, have combined medical problems affecting multiple organ systems, and intellectual...

Sponsor: dr. Laura C. G. de Graaff-HerderEnrolling: 6001 location
RECRUITINGPhase 1NCT06455826

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31...

Sponsor: PYC TherapeuticsEnrolling: 125 locations
RECRUITINGNCT06092346

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary...

Background: Pyrimidine and purine metabolism disorders (DPPMs) affect how the body metabolizes chemicals called pyrimidines and purines. DPPMs can cause dysfunctions throughout...

Sponsor: National Human Genome Research Institute (NHGRI)Enrolling: 9991 location
RECRUITINGNCT04665726

Natural History Study of Usher Syndrome ( Light4Deaf )

Clinical centres in the LIGHT4DEAF consortium have developed and will continue to improve a reliable, early molecular diagnosis and protocols for full clinical characterisation of...

Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsEnrolling: 4004 locations
RECRUITINGPhase 1 / Phase 2NCT06789445

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in...

Sponsor: BlueRock TherapeuticsEnrolling: 543 locations
RECRUITINGPhase 1 / Phase 2NCT05748873

Promising ROd-cone DYstrophy Gene therapY

This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase...

Sponsor: SparingVisionEnrolling: 336 locations
RECRUITINGNCT00254605

Retinal Imaging in Patients With Inherited Retinal Degenerations

The purpose of this study is to determine whether the structure and function of the human retina can be studied with high resolution in patients with inherited retinal...

Sponsor: University of California, San FranciscoEnrolling: 4001 location
RECRUITINGPhase 1NCT06291935

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations...

The goal of this phase 1 clinical trial is to learn about the safety and efficacy of a gene therapy, VG901, in patients with a rare disorder of the eye called Retinitis...

Sponsor: VeonGen Therapeutics GmbHEnrolling: 61 location
RECRUITINGPhase 2NCT07174726

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male...

The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to...

Sponsor: Beacon TherapeuticsEnrolling: 106 locations
RECRUITINGPhase 2NCT06912633

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of...

Sponsor: jCyte, IncEnrolling: 6014 locations
RECRUITINGPhase 1 / Phase 2NCT06787482

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy...

Sponsor: Ace Cells Lab LimitedEnrolling: 1002 locations
RECRUITINGPhase 2NCT06628947

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in...

Sponsor: Kiora Pharmaceuticals, Inc.Enrolling: 365 locations
RECRUITINGNCT05589714

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare...

This is an international, multicenter study with two components: Registry * A standardized genetic screening and a prospective, standardized, cross-sectional clinical data...

Sponsor: Jaeb Center for Health ResearchEnrolling: 150020 locations
RECRUITINGNCT05809635

Study of BEST1 Vitelliform Macular Dystrophy

The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy. The blinding disorder Best Vitelliform Macular...

Sponsor: Columbia UniversityEnrolling: 523 locations
RECRUITINGPhase 1NCT06319872

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and...

Sponsor: University of RochesterEnrolling: 151 location
RECRUITINGNCT05853107

Pilot Study of AuTNA I

The objective of the study is to evaluate: 1. Safety of AuTNA I for subretinal implantation in patients with retinitis pigmentosa; 2. Efficacy of AuTNA I for subretinal...

Sponsor: Eye & ENT Hospital of Fudan UniversityEnrolling: 71 location
RECRUITINGNCT02329210

Clinical Registry Investigating Bardet-Biedl Syndrome

Bardet-Biedl Syndrome (BBS) is a rare genetic disorder associated with a vast array of symptoms. The features of BBS are highly variable, even between siblings, making long-term...

Sponsor: Marshfield Clinic Research FoundationEnrolling: 12001 location
RECRUITINGPhase 1 / Phase 2NCT06891885

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years...

The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts...

Sponsor: Sumitomo Pharma America, Inc.Enrolling: 121 location
RECRUITINGNCT04639635

CNGB1 and Allied Disorders

Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes...

Sponsor: Columbia UniversityEnrolling: 206 locations
RECRUITINGPhase 2NCT06627179

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa...

Sponsor: Laboratoires TheaEnrolling: 8120 locations
RECRUITINGEarly Phase 1NCT05805007

Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of ZVS203e administered via subretinal injection in participants with...

Sponsor: Peking University Third HospitalEnrolling: 91 location
RECRUITINGPhase 1 / Phase 2NCT06591793

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a...

Sponsor: AAVantgarde Bio SrlEnrolling: 153 locations
RECRUITINGPhase 1 / Phase 2NCT06852963

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in...

This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31...

Sponsor: PYC TherapeuticsEnrolling: 166 locations
RECRUITINGNCT06982417

InsightRP2 Registry

InsightRP2 is a secure online patient registry specific to RP2-associated retinitis pigmentosa (RP). It is our goal to further the scientific understanding of this rare disease...

Sponsor: University of GöttingenEnrolling: 2001 location
RECRUITINGNCT06375239

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal...

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...

Sponsor: Ray Therapeutics, Inc.Enrolling: 1201 location
RECRUITINGNCT06323772

Natural History Study in Patients with PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa

The aim of the study is to apply a novel clinical investigation protocol in patients with Phosphodiesterase 6A (PDE6A), PDE6B and Rhodopsin (RHO)-based retinitis pigmentosa. This...

Sponsor: University Hospital TuebingenEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT05282953

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to...

A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS).

Sponsor: Kiora Pharmaceuticals, Inc.Enrolling: 483 locations

Showing 50 of 57 trials.Search all Retinitis Pigmentosa trials